Methotrexate: Bioavailability and pharmacokinetics

M. A. Campbell, D. G. Perrier, R. T. Dorr, D. S. Alberts, P. R. Finley

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Six adult patients with squamous cell carcinoma of the head and neck were treated with single low doses of methotrexate (MTX) (30 mg/m2) iv, im, and orally in the form of commercial tablets. A randomized crossover design was employed. Plasma concentrations were measured by a modified EMIT assay over a period of 24 hours following each dose. The mean (± SD) parameters following iv MTX were as follows: total-body clearance, 124 (36) ml/minute; V(ss), 0.56 (0.18) L/kg; V(γ), 0.69 (0.24) L/kg; and beta-half-life, 3.20 hours. The absolute systemic bioavailability of the oral tablets was 36% (±10%). After im administration, the systemic bioavailability was 93% (±14%). Dose-dependent gastrointestinal absorption is suggested as the mechansm for the low availability of the oral tablets. Administration of MTX by the oral route will require further study to determine the optimal method of dosing.

Original languageEnglish (US)
Pages (from-to)833-838
Number of pages6
JournalCancer Treatment Reports
Volume69
Issue number7-8
StatePublished - 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Methotrexate: Bioavailability and pharmacokinetics'. Together they form a unique fingerprint.

  • Cite this

    Campbell, M. A., Perrier, D. G., Dorr, R. T., Alberts, D. S., & Finley, P. R. (1985). Methotrexate: Bioavailability and pharmacokinetics. Cancer Treatment Reports, 69(7-8), 833-838.